Helen M. Colhoun

Sep 27, 2024 | radcliffecvrm.com | Helen M. Colhoun |John McMurray |Richard E. Pratley |Phyo T. Htoo

EASD 24 - We are joined by Dr Helen Coulhoun (University of Edinburgh, UK) to discuss the key findings of a prespecified analysis of the SELECT trial, which investigated the effectiveness of semaglutide in reducing major cardiac events in the presence of impaired kidney function in patients with overweight and obesity.

Sep 16, 2024 | healio.com | Erik Swain |Richard Smith |Helen M. Colhoun

You've successfully added to your alerts. You will receive an email when new content is published. Click Here to Manage Email Alerts We were unable to process your request. Please try again later. If you continue to have this issue please contact [email protected]. Key takeaways: In patients with obesity and heart disease, Wegovy lowered risk for CV events regardless of kidney function. The absolute risk difference was greatest in those with poor kidney function.

May 13, 2024 | nature.com | Ildiko Lingvay |Eric Barros |Helen M. Colhoun |Cintia Cercato |A. Michael Lincoff |Jorge Plutzky

AbstractIn the SELECT cardiovascular outcomes trial, semaglutide showed a 20% reduction in major adverse cardiovascular events in 17,604 adults with preexisting cardiovascular disease, overweight or obesity, without diabetes. Here in this prespecified analysis, we examined effects of semaglutide on weight and anthropometric outcomes, safety and tolerability by baseline body mass index (BMI).

Feb 23, 2024 | healio.com | Michael Monostra |Richard Smith |Helen M. Colhoun

You've successfully added to your alerts. You will receive an email when new content is published. Click Here to Manage Email Alerts We were unable to process your request. Please try again later. If you continue to have this issue please contact [email protected]. Key takeaways:Children aged 6 to 14 years in Scotland had a sharp increase in new-onset type 1 diabetes cases in 2021. Incidence rates of type 1 diabetes among children fell below Scotland’s 8-year average in 2022.

Nov 11, 2023 | nejm.org | A. Michael Lincoff |Helen M. Colhoun |John Deanfield |Scott Emerson

AbstractSemaglutide, a glucagon-like peptide-1 receptor agonist, has been shown to reduce the risk of adverse cardiovascular events in patients with diabetes. Whether semaglutide can reduce cardiovascular risk associated with overweight and obesity in the absence of diabetes is unknown.